07.21.26 -- Analyzing And Managing CDMO Project Risks Using Causal Mechanism And Effect Analysis

Learn how focused optimization and coordinated execution helped overcome technical uncertainty and enable faster progression to market readiness.

Strong IP protections drive Tennessee’s biotech growth by attracting investment, supporting research, fostering collaboration, and enabling innovators to deliver new therapies and technologies to patients.

Analytical labs are becoming strategic partners, enabling faster decisions, integrated expertise, and stronger collaboration across development, manufacturing, and quality.

For emerging biotechs looking to refine their development processes and boost their chances of commercial success, exploring these partnership opportunities could prove invaluable.

In our series on pre-filled syringes, we examine five key ways this delivery format is enhancing patient outcomes, not just through the medicine it contains, but through the device design itself.

Biotech visibility improves through real-time data and centralized platforms, enabling collaboration, faster decisions, reduced risk, and better partner alignment.

Successful tech transfer depends on solid documentation, early teamwork, clear expectations, proactive risk planning, and experienced partners to keep execution smooth and projects moving on schedule.

Lilith Baczynski highlights how the Fremont site’s scale, flexibility, and expert teams support global mammalian biologics manufacturing.

Gain practical strategies and regulatory insight on viral clearance studies, including virus selection, performance benchmarks, case studies, and submission-ready data for biologic products.

Delve into how a tailored development approach transformed a complex therapeutic protein into a candidate ready for early-stage clinical trials.

The journey of a novel bioconjugate into clinic is complex and uncertain. Uncover the particular challenges when moving a bioconjugate candidate from early development into clinic.